comparemela.com

Latest Breaking News On - Sam slutsky - Page 1 : comparemela.com

CG Oncology Reports Bladder Cancer Treatment - Orange County Business Journal

CG Oncology Reports Bladder Cancer Treatment - Orange County Business Journal
ocbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ocbj.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioMerck keytrudaSam slutskyArthur kuanAmerican urological association annual meetingDrug administrationAmerican cancer societyAmerican society of clinical oncologyShiong immunitybio incCg oncology incFerring pharmaceuticalsAmerican urological associationAnnual meetingSci capitalFast track designation

Astria Therapeutics, Inc (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript

Operator: Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update. At this time, all attendees are in a listen-only mode.

Andrew komjathyNoah clauserJill milneDavid shaw quantEun yangLiz higginsChristopher morabitoElizabeth higginsSam slutskySeema shorinAndrea matthewsAstria therapeutics incAstria therapeuticsCall transcript novemberAstria therapeutics quarter threeInvestor relations

LifeSci Capital Reaffirms Their Buy Rating on Immunovant (IMVT)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant (IMVT – Research Report) today and set a price target of $34.00..

New yorkUnited statesVentyx biosciencesSam slutskyImmunovant incLifesci capitalResearch reportStrong buy

LifeSci Capital Reaffirms Their Hold Rating on Rain Therapeutics (RAIN)

In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on Rain Therapeutics (RAIN – Research Report). The c.

Guggenheim michael schmidtSam slutskyRain therapeutics incLifesci capitalBrain therapeuticsResearch reportMichael schmidtMizuho securitiesTherapeutics inc

Mizuho Securities Keeps Their Buy Rating on Rain Therapeutics (RAIN)

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Rain Therapeutics (RAIN – Research Report).

Sam slutskyGraig suvannavejhAmylyx pharmaceuticals incRain therapeutics incMizuho securitiesBrain therapeuticsResearch reportAxsome therapeuticsBioxcel therapeuticsAmylyx pharmaceuticalsLifesci capitalTherapeutics inc

vimarsana © 2020. All Rights Reserved.